CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹82 Cr | ₹184 Cr | ₹622 Cr | ₹1,660 Cr | ₹2,972 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹82 Cr |
Mar2023 | ₹184 Cr |
Mar2022 | ₹622 Cr |
Mar2021 | ₹1,660 Cr |
Mar2020 | ₹2,972 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹82 Cr | -55.36 | |
Mar2023 | ₹184 Cr | -70.48 | |
Mar2022 | ₹622 Cr | -62.55 | |
Mar2021 | ₹1,660 Cr | -44.15 | |
Mar2020 | ₹2,972 Cr | - |
Compare Total Non-Current Liabilities of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹117,760.2 Cr | 3.3% | -4.8% | 6.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹418,744.0 Cr | -4.2% | -7.7% | 24.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹152,209.0 Cr | -0.6% | -5.6% | 57.5% | Stock Analytics | |
MANKIND PHARMA | ₹102,663.0 Cr | -0.7% | -13.8% | 18.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,705.3 Cr | -2.4% | -12.8% | 1.1% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,929.3 Cr | -0.3% | -2.1% | 24.5% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | 3.3% |
-4.8% |
6.5% |
SENSEX | 0.3% |
-1.8% |
8.6% |
You may also like the below Video Courses